TNF-α and the development of the neonatal immune system: Implications for inhibitor use in pregnancy

Razvan Arsenescu, Violeta Arsenescu, Willem J.S. De Villiers

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Inflammatory bowel diseases, Crohns disease, and ulcerative colitis have an unpredictable course during and after pregnancy (1). There is a great deal of interest in treating moderate to severe active inflammatory bowel disease with anti-tumor necrosis factor (anti-TNF) biologics in pregnant women (2). We lack definitive information about the effects of these agents on the development of the immune system of the human fetus and the newborn baby. Anti-TNF agents fall within US Food and Drug Administrations (FDA) category B regarding fetal risk, indicating that no adequate and well-controlled studies have been conducted in pregnant or nursing women. Here, we review animal studies (of both mice and nonhuman primates) that examine the role of TNF and its inhibitors in the normal development of the immune system.

Original languageEnglish (US)
Pages (from-to)559-562
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume106
Issue number4
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Immune System
Pregnancy
United States Food and Drug Administration
Biological Products
Ulcerative Colitis
Crohn Disease
Primates
Pregnant Women
Fetus
Nursing
Tumor Necrosis Factor-alpha
Newborn Infant

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{32d5669811104e0a85038aae368da7b8,
title = "TNF-α and the development of the neonatal immune system: Implications for inhibitor use in pregnancy",
abstract = "Inflammatory bowel diseases, Crohns disease, and ulcerative colitis have an unpredictable course during and after pregnancy (1). There is a great deal of interest in treating moderate to severe active inflammatory bowel disease with anti-tumor necrosis factor (anti-TNF) biologics in pregnant women (2). We lack definitive information about the effects of these agents on the development of the immune system of the human fetus and the newborn baby. Anti-TNF agents fall within US Food and Drug Administrations (FDA) category B regarding fetal risk, indicating that no adequate and well-controlled studies have been conducted in pregnant or nursing women. Here, we review animal studies (of both mice and nonhuman primates) that examine the role of TNF and its inhibitors in the normal development of the immune system.",
author = "Razvan Arsenescu and Violeta Arsenescu and {De Villiers}, {Willem J.S.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1038/ajg.2011.5",
language = "English (US)",
volume = "106",
pages = "559--562",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "4",

}

TNF-α and the development of the neonatal immune system : Implications for inhibitor use in pregnancy. / Arsenescu, Razvan; Arsenescu, Violeta; De Villiers, Willem J.S.

In: American Journal of Gastroenterology, Vol. 106, No. 4, 01.04.2011, p. 559-562.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TNF-α and the development of the neonatal immune system

T2 - Implications for inhibitor use in pregnancy

AU - Arsenescu, Razvan

AU - Arsenescu, Violeta

AU - De Villiers, Willem J.S.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Inflammatory bowel diseases, Crohns disease, and ulcerative colitis have an unpredictable course during and after pregnancy (1). There is a great deal of interest in treating moderate to severe active inflammatory bowel disease with anti-tumor necrosis factor (anti-TNF) biologics in pregnant women (2). We lack definitive information about the effects of these agents on the development of the immune system of the human fetus and the newborn baby. Anti-TNF agents fall within US Food and Drug Administrations (FDA) category B regarding fetal risk, indicating that no adequate and well-controlled studies have been conducted in pregnant or nursing women. Here, we review animal studies (of both mice and nonhuman primates) that examine the role of TNF and its inhibitors in the normal development of the immune system.

AB - Inflammatory bowel diseases, Crohns disease, and ulcerative colitis have an unpredictable course during and after pregnancy (1). There is a great deal of interest in treating moderate to severe active inflammatory bowel disease with anti-tumor necrosis factor (anti-TNF) biologics in pregnant women (2). We lack definitive information about the effects of these agents on the development of the immune system of the human fetus and the newborn baby. Anti-TNF agents fall within US Food and Drug Administrations (FDA) category B regarding fetal risk, indicating that no adequate and well-controlled studies have been conducted in pregnant or nursing women. Here, we review animal studies (of both mice and nonhuman primates) that examine the role of TNF and its inhibitors in the normal development of the immune system.

UR - http://www.scopus.com/inward/record.url?scp=79953795330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953795330&partnerID=8YFLogxK

U2 - 10.1038/ajg.2011.5

DO - 10.1038/ajg.2011.5

M3 - Article

C2 - 21468063

AN - SCOPUS:79953795330

VL - 106

SP - 559

EP - 562

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 4

ER -